MicroRNA-204 critically regulates carcinogenesis in malignant peripheral nerve sheath tumors

Meng Gong, Junrong Ma, Mi Li, Mingliang Zhou, Janet M. Hock, and Xijie Yu

Laboratory of Endocrinology and Metabolism, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, P.R. China (M.G., J.M., M.L., M.Z., X.Y.); Maine Institute for Human Genetics & Health, Bangor, Maine (M.G., J.M.H., X.Y.)

Malignant peripheral nerve sheath tumors (MPNSTs) are highly aggressive soft tissue sarcomas accounting for 3%–10% of all soft tissue sarcomas. Neurofibromatosis type 1 (NF1) is the most important known risk factor. MPNSTs are often diagnosed at an advanced stage when distant metastases have developed. Although surgical resection remains the main treatment for MPNSTs, complete surgical resection is rarely possible. The prognosis for patients with MPNSTs is poor. There is an urgent need for improved therapies. To this end, we investigated whether microRNA (miR), specifically miR-204, might be implicated in MPNSTs because it is located at a cancer-associated genomic region exhibiting high frequency of loss of heterozygosity in tumors. We show that miR-204 expression is downregulated in NF1 and non-NF1 MPNST tumor tissues and in tumor cell lines. Restoring miR-204 expression in MPNST cell lines STS26T (non-NF1), ST88-14 (NF1), and T265p21 (NF1) significantly reduces cellular proliferation, migration, and invasion in vitro. Restoring miR-204 expression in STS26T decreases tumor growth and malignant progression in vivo. We also report that miR-204 inhibits Ras signaling and expression of high mobility group gene A2. These findings support the hypothesis that miR-204 plays critical roles in MPNST development and tumor progression. miR-204 may represent a novel biomarker for diagnosis and a candidate target with which to develop effective therapies for MPNSTs.

Keywords: HMGA2, miR-204, MPNSTs, NF1, RAS.
at younger ages and to have a poor prognosis. These facts suggest that NF1 and deregulation of its signaling pathway likely play important roles in carcinogenesis of MPNSTs. The NF1 protein, neurofibromin, contains a highly conserved guanosine triphosphatase (GTPase)–activating protein–related domain (GRD) that converts active Ras-GTP into inactive Ras-GDP in the Ras signaling pathway. Loss of NF1 is considered a tumor-promoting event, leading to constitutively increased activation of Ras and its downstream effectors, thus initiating neurofibromas. However, loss of neurofibromin alone is not sufficient for malignant transformation, implying that additional genetic alterations are necessary for the development of MPNSTs. Mutations of the TP53 locus were reported in up to 75% of MPNSTs. Mice that harbor both NF1 and TP53 mutations develop MPNSTs. Associated with development of MPNSTs are homozygous deletions of the CDKN2A gene, which encodes both p16INK4A and p14ARF in alternative reading frames, and inactivation of CDKN1B, a gene that encodes the p27(Kip1) cell-cycle regulator. Also believed to contribute to MPNST pathogenesis are overexpression of epidermal growth factor receptor (EGFR), platelet-derived (PD)GFR–α and PDGFR–β, c-Kit, matrix metalloproteinase 13 (MMP13), and genes involved in cell proliferation (MKI67, TOP2A, CCNE2), apoptosis (BIRC5/Survivin, TP73), and the signaling pathways of Ras (RASF2, HMMR/RHAMM) and Hedgehog-Gli (DHH, Ptch2). Despite these findings, there is insufficient knowledge of critical pathways initiating and promoting progression of MPNST, limiting the ability to develop effective treatments.

MicroRNAs (miRNAs, miR-) are a new class of small noncoding RNAs of about 19–25 nucleotides (nt) that function as negative posttranscriptional gene regulators. miRNAs hybridize to the 3′ untranslated region (UTR) of target mRNAs and repress translation or mediate mRNA cleavage. miRNAs critically regulate tumorigenesis and progression by targeting oncogenes, tumor suppressor genes, or genes related to proliferation, angiogenesis, and apoptosis. Different tumor types and tumors at various differentiation stages exhibit unique miRNA profiles. miRNAs show promise as potential biomarkers for cancer diagnostics, progression, and response to treatment. In considering a role for miRNAs in MPNSTs, Subramanian et al. reported that miR-34a was downregulated in MPNSTs, compared with neurofibromas. They concluded that p53 inactivation and subsequent loss of expression of miR-34a may contribute to MPNST development. We reported that miR-10b was upregulated in primary Schwann cells isolated from NF1 neurofibromas and in cell lines and tumor tissues from NF1 MPNSTs, but not in cell lines and tumor tissues from non-NF1 MPNSTs. Our prior study indicated that miR-10b may be an NF1-specific regulating factor that targets neurofibromin and Ras signaling to regulate NF1 tumorigenesis. Except for these 2 miRNAs, pathological roles of other miRNAs in MPNSTs are largely unexplored. One candidate miRNA of interest, miR-204, is located at the cancer-associated genomic region 9q21.1–q22.3 locus and exhibits a high frequency of loss of heterozygosity in tumors. miR-204 is also significantly downregulated in broad types of tumors such as breast cancer, prostate cancer, and kidney cancer, suggesting a role for miR-204 as a tumor suppressor gene. In the present study, our aims were to determine whether miR-204 might play a role in carcinogenesis in MPNSTs.

Materials and Methods

Human tissues were obtained under human subject protocols approved by the institutional review boards at Maine Institute for Human Genetics and Health and West China Hospital, Sichuan University. Informed consent was obtained from each subject or the subject’s guardian. Animal use was in accordance with the guidelines of the Institutional Animal Care and Use Committee at the Jackson Laboratory and West China Hospital, Sichuan University.

Cell Culture

Human NF1-associated MPNST cell lines ST8814 and T265p21 and the non-NF1-associated MPNST cell line ST262T (kindly supplied by Dr. Nancy Ratner) were maintained in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum (FBS). NF1 mutation status for these 3 cell lines has been reported previously by other groups.

Analysis of miRNA Expression by Microarray and qRT-PCR

RNA was extracted from cells or tumor tissues using the RNeasy miRNA kit (Qiagen). miRNA microarrays were performed by LC Sciences. Quantitative (q) real-time and reverse transcriptase (RT) PCR were performed in a 2-step reaction using Taqman miRNA assays (Applied Biosystems), according to the manufacturer’s protocols. U6 was used as the internal control. The 2−ΔΔCT method, described by Livak and Schmittgen, was used to analyze the data.

Stable Overexpression of miR-204 in MPNST Cell Lines

In order to obtain stable cell lines with high miR-204 expression, miR-204 precursor genes were transfected into MPNST cell lines by a lentiviral expression system. Lentivirus was prepared using the LentiSuite for Lenti-miR-204 miRNA Precursor Expression Construct (System Biosciences) according to the manufacturer’s protocol. The pGreenPuro Scramble Hairpin Control Construct (System Biosciences) was used as the control. Lentiviral infection was performed according to the manufacturer’s protocol. Stably high-expressing cell lines were selected out by single colony screening of cells cultured in 96-well plates. Expression
of miR-204 was assayed by qRT-PCR. Infected cells were analyzed by the various assays described below.

**MTT Proliferation Assay**

Infected cells at 70%–80% confluence were serum-starved for 24 h, then cultured at a density of 2000/well in 96-well plates at 5% CO2, 37°C. At selected time points, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium) was added at a final concentration of 0.5 mg/mL. After 4 h incubation, medium was removed, and purple blue sediment was dissolved in 150 μL dimethyl sulfoxide. The relative optical density (OD) for each well was determined using a Wells cell line (Labsystems).

**Colony Formation**

Infected cells were seeded at a density of 200/well in 6-well plates in 2% FBS-supplemented medium. After culturing for 14 days, cells were fixed with 4% paraformaldehyde for 20 min and stained with 0.1% crystal violet for 30 min. Colonies were counted using bright-field microscopy.

**Cell Migration and Invasion**

Serum-starved were trypsinized, centrifuged, and resuspended in 0.1% FBS-supplemented medium without added growth factor. Cells were plated at a density of 2.5 × 104/well for STS26T cells or 5.0 × 104/well for ST8814 and T26sP2a1 cells in a transwell insert (3 μm pore size; BD Biosciences) for the migration assay or in a matrigel-coated, growth-factor-reduced, invasion chamber (8 μm pore size; BD Biosciences) for the invasion assay. Ten percent FBS-containing medium was added into 24-well plates as a chemoattractant. After 6 h incubation for the migration assay, or after 22 h incubation for the invasion assay, cells were fixed with 4% paraformaldehyde for 1 h. Cells on the apical side of each insert were removed by mechanically scraping. Cells that migrated to the basal side of the membrane were stained with 0.1% crystal violet and visualized under a Zeiss Axiovert 200M microscope. Cell numbers were quantified in an automated mode using the Metamorph analysis software.

**Western Blotting**

Cells were lysed in radio-immunoprecipitation assay buffer containing Halt Protease Inhibitor Cocktail (Pierce). Protein concentration was determined with the Quick Start Bradford Protein Assay kit (Bio-Rad). The blotting membrane was incubated overnight at 4°C with different primary antibodies: anti-p44/42 MAP kinase (1:1000; Cell Signaling Technology), anti-phospho-p44/42 MAPK (Thr202/Tyr204) (1:1000; Cell Signaling), anti–high mobility group (HMGA2) A2 (1:500; Sigma), and anti–β-actin (1:1000; Sigma). The blots were incubated for 1 h at room temperature with anti-mouse immunoglobulin (Ig)G (Chemicon) as a horseradish peroxidase–conjugated secondary antibody. Signals were visualized using electrogenerated chemiluminescence (CL) plus CL substrate (Amersham).

**HMGA2 3′ UTR Reporter Assay**

The 3′ UTR of the HMGA2 gene was amplified from human genomic DNA using primers (forward: 5′-tttacta gttgtcagtgtatctttcatcagcta-3′; reverse: and 5′-tttgagctg aagagatggraaactaagcggaa-3′) and subcloned into the 3′ UTR of the pMIR-REPORT miRNA reporter vector (Ambion). The recombinant plasmid was confirmed by DNA sequencing. Point mutations within the target sequence for miR-204 in the 3′ UTR (HMGA2 3′ UTRm) were generated by the QuickChange II XL site-directed mutagenesis kit (Stratagene) using primers (forward: 5′-aaaaaatcgaagcagcaacttggc-3′; reverse: 5′-ttac tcagttgtgaaaataaatgtcctctctc-3′). The plasmids containing the HMGA2 3′ UTRm were sequenced to confirm replacement of the targeted residues. The lentivirus mentioned above was used to stably transfect the miR-204 precursor gene or control the sequence into 293T cells. Transfected cells were further cotransfected with pMIR reporter vector with the HMGA2 3′ UTR or the HMGA2 3′ UTRm together with the pMIR-REPORT beta-galactosidase reporter control vector. Cells were collected 24 h after transfection. The ratio of beta-galactosidase to firefly luciferase was measured with the Promega Dual Luciferase Assay kit.

**Tumor Cell Xenograft**

STS26T cells infected with miR-204 virus or control virus were cultured under equivalent conditions. Dissociated cells were collected, rinsed thoroughly, and resuspended in cold 30% matrigel in phosphate buffered saline (BD Biosciences) at a density of 5 × 106/mL. Eight-week old NOD SCID IL-2r gamma −/− (NSG) male mice (10 mice per group) were anesthetized with isoflurane. A cell suspension (1 × 106 cells in 200 μL) was injected subcutaneously into the back of each mouse. Mice were observed daily for the first 3–5 days postoperatively to ensure that the injection site was healthy. Mice were sacrificed on the 14th day after injection. Tumor tissue samples were collected. Tumor volume was calculated by the formula 1/2 ab2, where a is the long axis and b is the short axis. Paraffin-embedded sections of tumor tissues were stained with hematoxylin and eosin (H&E) or Masson’s trichrome stains.

**Statistical Analyses**

Analyses were performed with JMP 8.0 software (SAS). An analysis of variance was used to compare multiple groups, followed by pairwise comparisons if significant differences were detected; a Tukey–Kramer test was used for comparison with a control group, and
Dunnett’s test was used for comparison of all groups. Unpaired *t* tests were used to compare 2 groups. Differences were considered statistically significant at *P* < .05 in a 2-tailed test. Data are expressed as means ± SEM.

**Results**

**Downregulation of miR-204 in Tumor Tissues and Cell Lines from NF1 and non-NF1 MPNSTs**

To investigate miRNA expression in tumor tissues, total RNA was isolated from human MPNSTs and benign NF1 neurofibroma tissues; miRNA profiles were studied by miRNA microarray. Twenty-four miRNAs were identified as downregulated, and 6 miRNAs were upregulated in MPNSTs rather than in neurofibromas (Supplementary material, Table S1). miRNAs with a high expression level (density over 300) in either the MPNST group or the neurofibroma group were selected for confirmation by qRT-PCR in tumor tissues and MPNST cell lines. Compared with benign neurofibromas, miR-204 was the only miRNA whose expression was significantly downregulated, while miR-96 was the only miRNA whose expression was significantly upregulated in tumor tissues as well as cell lines from NF1 and non-NF1 MPNSTs (Fig. 1 and Supplementary material, Fig. S1). The consistent deregulation of miR-204 and miR-96 in MPNST tumor tissues and cell lines and in NF1 and non-NF1 genotypes suggests that they may contribute to the carcinogenesis mechanisms in MPNSTs. To further investigate the functional significance of deregulated miRNAs observed in MPNSTs, ST8814 cells were transfected with antisense inhibitors for miR-96, mimic enhancers for miR-204, or with negative controls. Enhancing miR-204 significantly decreased cell proliferation at days 3, 4, and 5 and migration into ST8814 cells, while inhibiting miR-96 expression did not affect proliferation at most time points tested or migration into ST8814 cells (Supplementary material, Fig. S2). These results suggest that miR-204 plays an important role in MPNST tumorigenic mechanisms, while miR-96 may have only a limited role in MPNSTs. Therefore, miR-204 was chosen for further study.

**Restoring miR-204 Expression Reversed Abnormal Cellular Behaviors in NF1 and Non-NF1 MPNST Cell Lines In Vitro**

To further investigate the role of miR-204 in MPNST carcinogenesis, the miR-204 gene was stably transfected using a lentiviral system into the NF1 MPNST cell lines, ST8814 and T265p21, and the non-NF1 MPNST cell line, STS26T. This system allows miRNA expression from the constitutive cytomegalovirus promoter. The

---

**Fig. 1. Downregulation of miR-204 expression in MPNSTs.** Total RNA was isolated from human MPNST tumor tissues or cell lines. (A) Total RNA was labeled and hybridized on miRNA microarrays. Signals represent median signal values of 3 times. miR-204 along with a few other miRNAs showed low expression levels in NF1 and non-NF1 MPNST tumor tissues (1_1, 1_2, 1_3, 1_4: neurofibromas; 2_2, 2_3: NF1 MPNSTs; 2_4: non-NF1 MPNSTs). (B) The expression of miR-204 was further studied by qRT-PCR. miR-204 expression was significantly lower in NF1 and non-NF1 MPNST tumor tissues, in NF1 MPNST cell lines (ST8814 and T265p21), and the non-NF1 MPNST cell line (STS26T) compared with neurofibromas (**P < .01; ***P < .001; n = 3–12).  

---

**Fig. 2. Restoring miR-204 expression in NF1 and non-NF1 MPNST cell lines.** miR-204 gene was stably transfected into human NF1-associated MPNST cell lines ST8814 and T265p21 and the non-NF1-associated MPNST cell line STS26T with a lentiviral system. Fluorescence microscopy and qRT-PCR assay were used to select out the colonies with higher expression of miR-204. Assay by qRT-PCR showed that miR-204 expression was significantly higher in ST8814, T265p21, and STS26T cells with exogenous miR-204 gene than in the controls (**compared with controls, *P < .001, n = 3).
positive expressing cells can be sorted and monitored as the system contains copepod green fluorescent protein (copGFP) as a reporter. Multiple colonies positive for copGFP in each cell line were selected using fluorescence microscopy. Compared with colonies transfected with the control construct, colonies transfected with mir-204 exhibited significantly higher expression levels of mir-204 (Fig. 2, P < .001).

In proliferation assays using MTT activity, restoration of mir-204 expression in STS26T, ST8814, and T265p21 cells significantly reduced cellular proliferation at most time points during 6–7 days of culture (Fig. 3A). Colonies formed by mir-204 transfected cells were much smaller than those formed by control cells (reduced 38% in STS26T, 37% in T265p21, 27% in ST8814; Fig. 3B, P < .05). The reduction of proliferation was most dramatic in the non-NF1 MPNST cell line STS26T (Fig. 3A and B). These results suggest that mir-204 inhibits cell proliferation in both NF1 and non-NF1 MPNST cell lines.

Restoring mir-204 reduced the cellular migration by 26% in STS26T, 62% in ST8814, and 35% in T265p21 (Fig. 4A, P < .05). Restoring mir-204 also reduced cellular invasion by 53% in STS26T, 72% in ST8814, and 48% in T265p21 (Fig. 4B, P < .05). The maximal inhibition of migration and invasion occurred in the NF1 MPNST cell line ST8814. These results support the hypothesis that miR-204 may play an important role in regulation of both NF1 and non-NF1 MPNST development and progression.

Restoring miR-204 Expression Inhibited MPNST Tumor Formation In Vivo

Tumor cell xenografts in immunodeficient mice represent standard strategies to model human tumor cell growth in vivo. Prior research reported that ST8814 and T265p21 cell xenografts in immunodeficient mice either failed to form tumors35,36 or took up to 3 months to form tumors.37 Therefore, we selected STS26T cells for xenografts. All mice exhibited tumor growth within 14 days after STS26T cells were implanted. Average tumor volume of the miR-204 group was about a fourth (42.3 mm³ vs 178 mm³, P < .001, Fig. 5A and B) of the control group. Tumor xenografts in control mice were irregular in shape and hard to...
dissect from surrounding normal tissues. In contrast, most tumors in the miR-204-expressing cell xenografts were close to spherical in shape and easy to dissect. H&E staining demonstrated less cell mitosis and invasion in the miR-204 group compared with controls (Fig. 5C and D). Masson trichrome staining showed that collagen around tumor xenograft tissues in controls was thin and noncontiguous. In contrast, collagen in the miR-204–expressing cell xenografts was thick, integrated, and continuous (Fig. 5E and F). These in vivo data indicate that increasing miR-204 expression reduced tumor size and malignancy (tissue invasion), supporting the hypothesis that miR-204 plays a key role in regulating malignant transformation and progression in MPNSTs.

miR-204 Modulated RAS Signaling and Inhibited HMGA2 Expression to Regulate Carcinogenesis Progression in MPNSTs

Using Web-based informatics software (miRecords, http://mirecords.biolead.org/index.php), we identified certain genes in the Ras signaling pathways as candidate targets for miR-204 (Table 1). Because most NF1-related tumors display abnormal Ras signaling pathways and because genes involved in the Ras pathways, such as RASF2 and HMMR/RHAMM, were deregulated in MPNSTs, we wondered if miR-204 targets Ras signaling pathways in MPNST cell lines. Compared with controls, both NF1 (ST8814 and T265p21) and non-NF1 (ST26T) MPNST cells transfected with miR-204 exhibited less phosphorylated extracellular-signal-regulated kinase (ERK) after serum stimulation (Fig. 6A). This result indicated that miR-204 may target molecules within Ras signaling pathways.

Our bioinformatics analysis showed that miR-204 may also target HMGA2, suggesting that additional mechanisms could contribute to carcinogenesis under miR-204 control (Table 1). Interestingly, HMGA2 expression is significantly higher in invasive than in noninvasive tumors and is strongly upregulated in all MPNSTs. Compared with controls, NF1 (ST8814 and T265p21) and non-NF1 (ST26T) MPNST cells transfected with miR-204 exhibited a lower level of HMGA2 (Fig. 6B). To further investigate whether miR-204 targets HMGA2 directly, we cloned the HMGA2 3' UTR and placed it in the 3' UTR of a luciferase reporter expression cassette. Cotransfection in 293T cells with either the miR-204 expression vector or a control vector showed that overexpression of miR-204 significantly reduced luciferase activity from the construct containing the HMGA2 3' UTR (Fig. 6D; P < .001). miR-204 failed to reduce luciferase activity when its target sequence in the HMGA2 3' UTR was mutated (Fig. 6D). These results indicate that miR-204 likely directly targets the 3' UTR of HMGA2 mRNA, representing an alternative pathway that could regulate malignant transformation and progression in MPNSTs.

Discussion

miRNAs are implicated in the carcinogenesis of several tumors and are under investigation as candidate oncology therapeutic targets. miR-204 is located within the sixth intron of the host gene transient receptor potential melastatin 3 cation channel (TRPM3, NM_020952) and is transcribed in the same direction as TRPM3. miR-204 appears to be an important regulator in cell differentiation, in apoptosis, in stress response and inflammation, in lens and retinal development, and in the maintenance of axonal structure and function. Interestingly, miR-204 is located within the cancer-associated genomic region 9q21.1–q22.3 locus that exhibits high frequency of loss of heterozygosity in some types of tumors, such as squamous cell carcinoma of the head and neck. Compared with normal tissues,
miR-204 expression is significantly lower, by 0.07% to 5%, in tumors in 5 of the 9 tissue types (brain, kidney, ovary, hematological cells, and colon). Expression of miR-204 is lower in the National Cancer Institute–tumor cell line panel compared with its expression in 13 normal tissues. Significant downregulation of miR-204 was recently reported in a subtype of acute myeloid leukemia-bearing cytoplasmic mutated nucleophosmin and in 3 Burkitt B-cell lymphoma cell lines. miR-204 is also downregulated in gastric cancer cells and gastric carcinomas. Taken as a whole, these reports strongly suggest that miR-204 functions as a tumor suppressor.

In the present study, we found that miR-204 was downregulated in NF1 and non-NF1 MPNST tumor tissues, in NF1 MPNST tumor cell lines ST8814 and T265p21, and in the non-NF1 MPNST tumor cell line STS26T, supporting the hypothesis that downregulation of miR-204 occurs in MPNSTs. Restoring miR-204 expression in NF1 and non-NF1 MPNST tumor cell lines significantly reduced cellular proliferation, migration, and invasion in vitro (Figs 3 and 4). Importantly, restoring miR-204 expression in non-NF1 MPNST tumor cell lines significantly reduced tumorigenesis in vivo (Fig. 5). Our data support the concept that miR-204 functions as a tumor suppressor and may critically regulate tumor formation and malignant progression in MPNSTs.

Multiple lines of evidence support the importance of the Raf–mitogen-activated protein kinase–ERK pathway, downstream of Ras in regulating proliferation of MPNSTs in general, and of NF1-related MPNSTs in particular. Phosphorylated ERK (pERK) is a surrogate marker for activated Ras. The tumorigenic effect of pERK is supported by its overexpression in more
than 90% of MPNST tissues compared with its expres-
sion in 21% of benign neurofibromas. In the present
study, we report that both NF1 and non-NF1 MPNST

cell lines with exogenous miR-204 exhibited a lower
level of pERK after serum stimulation (Fig. 6A), indicat-
ing that miR-204 targets molecules within Ras signaling
pathways. It has been reported that miR-204 is downre-
gulated in gastric cancer cells and gastric carcinomas. miR-204 inhibited ezrin, which activates Ras by remod-
eling the cortical actin cytoskeleton and has been im-
plicated in metastatic progression of certain cancers.
By contributing to ezrin upregulation, miR-204 downre-
gulation represents a novel mechanism for aberrant Ras
activation in gastric carcinogenesis. It seems plausible
that miR-204 targets molecules such as ezrin, which may
deregulate Ras signaling in a way that promotes malig-
nant transformation and progression in MPNSTs.

Our bioinformatics analysis suggested that miR-204
might target HMGA2, part of the high mobility group
HMGA protein family, which are architectural
transcription factors that both positively and negatively
regulate the transcription of a variety of genes. Overexpression of HMGA2 was associated with mali-
gnant transformation, because HMGA2 expression was
significantly higher in invasive than in noninvasive
tumors. Supporting this concept, inactivation of the
HMGA2 gene prevented cell transformation. Compared with its expression in normal human
Schwann cells, HMGA2 was upregulated in all
MPNSTs, implicating HMGA2 as a factor in the pro-
motion of MPNST carcinogenesis. Indeed, HMGA2 ex-
pression was reduced by about 70% when miR-204
function was ectopically enhanced in the JSQ3 squa-
mous cell carcinoma of the head and neck cell line.

Our data showed that NF1 (ST8814 and T265p21)
and non-NF1 (STS26T) MPNST cells transfected with
miR-204 exhibited less HMGA2 than their controls
(Fig. 6B). Further study confirmed that miR-204
targets HMGA2 directly (Fig. 6D). We speculate that
miR-204 may contribute to deregulation mechanisms

### Table 1. Predicted targets for miR-204

<table>
<thead>
<tr>
<th>Symbol</th>
<th>Description</th>
<th>Miranda</th>
<th>Mirtarget2</th>
<th>Pictar</th>
<th>Pita</th>
<th>Rhnahybrid</th>
<th>Targetscan</th>
</tr>
</thead>
<tbody>
<tr>
<td>CCND2</td>
<td>Cyclin D2</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>CCNI2</td>
<td>Cyclin I family, member 2</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>CCNJ</td>
<td>Cyclin J</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>CCNT2</td>
<td>Cyclin T2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>CCNY</td>
<td>Cyclin Y</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>CNNM4</td>
<td>Cyclin M4</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>CNTD1</td>
<td>Cyclin N-terminal domain containing 1</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>HDAC9</td>
<td>Histone deacetylase 9</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>HMGA2</td>
<td>High mobility group AT-hook 2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>RAB10</td>
<td>RAB10, member Ras oncogene family</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>RAB13</td>
<td>RAB13, member Ras oncogene family</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>RAB14</td>
<td>RAB14, member Ras oncogene family</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>RAB1A</td>
<td>RAB1A, member Ras oncogene family</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>RAB22A</td>
<td>RAB22A, member Ras oncogene family</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>RAB27B</td>
<td>RAB27B, member Ras oncogene family</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>RAB40B</td>
<td>RAB40B, member Ras oncogene family</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>RAB5C</td>
<td>RAB5C, member Ras oncogene family</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>RAB6IP1</td>
<td>RAB6 interacting protein 1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>RAP2C</td>
<td>RAP2C, member of Ras oncogene family</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>RASL10A</td>
<td>Ras-like, family 10, member A</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>RASSF2</td>
<td>Ras association (RalGDS/AF-6) domain family member 2</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>RASSF8</td>
<td>Ras association (RalGDS/AF-6) domain family member 8</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>RHOT1</td>
<td>Ras homolog gene family, member T1</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>TP53INP1</td>
<td>Tumor protein p53 inducible nuclear protein 1</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>TP63</td>
<td>Tumor protein p63</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>TPRG1L</td>
<td>Tumor protein p63 regulated 1–like</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>TRIP1</td>
<td>TP53 regulated inhibitor of apoptosis 1</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>COL14A1</td>
<td>Collagen, type XIV, alpha 1</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>COL5A1</td>
<td>Collagen, type V, alpha 1</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>DNA2</td>
<td>DNA replication helicase 2 homolog (yeast)</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>MMP16</td>
<td>Matrix metallopeptidase 16 (membrane-inserted)</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
</tbody>
</table>

Abbreviations: 1, interaction predicted, 0 interaction not predicted. Molecules in the Ras signaling pathways are highlighted.
Fig. 6. miR-204 inhibited RAS signaling and HMGA2 expression. (A) NF1 and non-NF1 MPNST cells with the exogenous miR-204 or the control construct were serum-starved for 24 h and then stimulated with serum-free medium (vehicle, VEH) or medium supplemented with 10% FBS for 10 min. Phosphorylated ERK and total ERK were studied by Western blotting. Compared with the VEH controls, treatment with 10% FBS increased phosphorylated ERK in all 3 MPNST cell lines. Cells with the exogenous miR-204 showed less phosphorylated ERK than cells with the control construct. (B) MPNST cells with the exogenous miR-204 or the control construct were serum-starved for 24 h. The expression of HMGA2 was studied by Western blotting. Compared with the controls, HMGA2 expression was lower in MPNST cells with the exogenous miR-204. (C) The 3′ UTR of the HMGA2 gene was analyzed by TargetScan, and a target sequence for miR-204 was identified. The strategy to make point mutations within the target sequence was listed as HMGA2–3′ UTRm. (D) The miR-204 precursor gene or the control was stably transfected into 293T cells. The transfected cells were further cotransfected with pMIR reporter vector with HMGA2 3′ UTR or HMGA2 3′ UTRm. The Dual Luciferase Assay kit was used to perform the HMGA2 3′ UTR reporter assay. Overexpression of miR-204 reduced the levels of luciferase activity by about 40% in the cells containing the HMGA2 3′ UTR (HMGA2 3′ UTR) but not in the cells with mutated seed sequence (HMGA2 3′ UTRm). These results indicated that HMGA2 3′ UTR was directly targeted by miR-204 (***P < .001 vs control; n = 3).
promoting progression of MPNSTs via HMGA2 pathways.

Our data suggest that miR-204 may critically regulate malignant transformation and progression in MPNSTs. It is still not clear whether miR-204 alone is sufficient to promote carcinogenesis in MPNSTs. Subramanian et al.\(^2\) reported that p53 inactivation and subsequent loss of expression of miR-34a may contribute to MPNST development. Our earlier research reported that miR-10b targets neurofibromin and Ras signaling to regulate NF1 tumorigenesis.\(^3\) In the present study, we found that miR-204 is downregulated in NF1 and non-NF1 MPNST tumor tissues, as well as in tumor cell lines. Restoring miR-204 expression in MPNST cell lines significantly reduced cellular proliferation, migration, and invasion in vitro and tumor growth and malignant transformation in vivo. We speculate that miR-204 may cooperate with other miRNAs, such as miR-10b and miR-34a, to promote MPNST development and progression. These miRNAs may represent novel selective and specific candidate targets for more effective therapies of MPNSTs.

**Supplementary Material**

Supplementary material is available at *Neuro-Oncology* online (http://neuro-oncology.oxfordjournals.org/).

**Acknowledgments**

Some work for this study was conducted by Dr. M. Gong in Dr. Yu’s Maine Institute of Human Genetics and Health laboratory at the Jackson Laboratory, Bar Harbor, ME.

**Conflict of interest statement.** None declared.

**Funding**

National Natural Science Foundation of China (No. 30872632, No. 81072190 to X. Yu; No. 81101920 to J. Ma); US Army Medical Research Command research contract (W81XWH-07-02-0116 to J. Hock).

**References**


